Analyst Research Report Snapshot

Title:

Eli Lilly and Company

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

17 Feb 2014

Pages:

64

Type:

AcrobatPDF

Companies referenced:

LLY.N

Available for Immediate Download
Summary:

Eli Lilly and Company - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Eli Lilly and Company required for business and competitor intelligence needs - A study of the major internal and external factors affecting Eli Lilly and Company in the form of a SWOT analysis - An in-depth view of the business model of Eli Lilly and Company including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Eli Lilly and Company - Intelligence on Eli Lilly and Companynv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Eli Lilly and Company, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Eli Lilly and Company (Lilly or ‘the company’) is one of the largest global, research-based pharmaceutical companies. The company's primary products are in the therapeutics areas of neuroscience, endocrinology, oncology, cardiovascular and animal health. The company primarily operates in the US, Europe and Japan. Lilly is headquartered in Indianapolis, Indiana and employed about 38,080 people as of December 31, 2011. The company recorded revenues of $24,286.5 million during the financial year ended December 2011 (FY2011), an increase of 5.2% over FY2010. The increase in revenues was primarily driven by the collective growth of Cymbalta, insulin products, animal health products, Alimta, Effient, and Cialis. The operating profit of the company was $5,349.5 million in FY2011, a decrease of 18% over FY2010. The net profit was $4,347.7 million in FY2011, a decrease of 14.2% over FY2010. Reasons to Purchase: - Gain understanding of Eli Lilly and Company and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Eli Lilly and Company as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Eli Lilly and Company’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.